Tapering Heart Failure Medication in Patients With Heart Failure With Recovered Ejection Fraction; Open Label Prospective Random Trial

ConditionsHeart Failure Ejection Fraction Recovery of Function

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorChungnam National University Hospital

About this trial

Study start date is on Nov 27th 2024.

A patient with an initial ejection fraction (EF) of less than 40%, whose follow-up shows an improvement to an EF of 50% or higher, along with the left ventricular end-diastolic diameter returning to the normal range and taking 3 more heart failure medication randomed to drug tapering group ( RAS blocker or beta blocker) or continuing medication group.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

initial echocardiogram ejection fraction less than 40%

follow up echocardiogram ejection fraction over 50% and LVEDD index normal range

NTprobnp criteria

eGFR ≥60 ; less 440

Disqualifiers

under age 18 year

uncontrolled BP ( over 150/90)

coronary revascularization within 6 months

significant valve disease

Trial design

Design model

Parallel

Treatments tested in this trial

RAS blocker tapering group
Drug
RAS blocker tapering out
Beta blocker tapering out
Drug
Beta blocker tapering out group

Treatment groups

150 Participants

are divided into 3 treatment groups

Group A: RAS blocker tapering armActive comparator 2 interventions

Group B: Beta blocker tapering armActive comparator 0 interventions

Group C: ControlPlacebo comparator 0 interventions

Trial outcomes

Primary outcomes

Heart failure relapse

LVEF 10% drop, EF less than 50 %, LVIDd/BSA 10% increase, over 33mm/m\^2

Time frame

From enrollment to the end of treatment at 18 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Chungnam National University Hospital

Lead sponsor

Source ClinicalTrials.gov

Apply now